ACCESS Newswire·Oct 6, 2026, 9:00 AM ET

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi

JAGX

Jaguar Health's subsidiary Napo Pharmaceuticals is a sponsor of the 2nd Best of Elite Ped-GI meeting in Abu Dhabi & will host a panel on October 30, 2026, titled "Intestinal Barrier Beyond Total Parenteral Nutrition (TPN)".
The panel discussion features Dr. Mohamad Miqdady, Dr. Christos Tzivinikos, & Dr. Pravin Chaturvedi, who serves as Napo's & Jaguar's Chief Scientific Officer.
Dr. Miqdady, Division Chief at Sheikh Khalifa Medical City, & Dr. Tzivinikos, Chairman of the meeting & founder of the Pediatric GI Department at Al Jalila Children's Specialty Hospital, are both involved in clinical evaluations of crofelemer for pediatric intestinal failure patients.
Data presented at the June 2026 ESPGHAN Meeting showed that oral liquid crofelemer reduced weekly parenteral support needs & parenteral support normalized to body weight in pediatric patients with microvillus inclusion disease (MVID) & short bowel syndrome (SBS) over one year, with no significant safety abnormalities.
Napo remains focused on its global development program for crofelemer powder for oral solution as adjunctive therapy for rare intestinal failure diseases, targeting a New Drug Application (NDA) filing for MVID in mid-2027.
A recent Rareatives article highlighted the story of a child with MVID, emphasizing the value of family perspectives & collaboration with clinicians in managing rare intestinal diseases.
Jaguar Health is a commercial-stage company developing plant-derived medicines, while Napo focuses on commercializing crofelemer for rare gastrointestinal disorders with intestinal failure.